TTrialPathMatch Me to Trials
← Back to trials
RecruitingBronchiolitis Obliterans SyndromeChronic Lung Allograft DysfunctionLung Transplantation

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation. The main questions it aims to answer are: * Is LAM-001 safe in these patients? * Is LAM-001 effective in slowing BOS progression? Participants will: * Be randomly assigned to inhale either LAM-001 or placebo (a look-alike substance that contains no active drug) daily for 48 weeks * Attend 10 study visits (mixture of in-person and telehealth) over the 48 week period * Undergo pulmonary function testing, bronchoscopy, lab testing, and physical examination * Submit weekly home spirometry monitoring Researchers will compare participants assigned to LAM-001 versus placebo to see if LAM-001 is safely tolerated and to assess the effectiveness of LAM-001 on slowing BOS progression.

Sponsor: Steven Hays, MD

You may qualify if…

  • ✓ Age \> 18 years old
  • ✓ Recipient of a double pulmonary allograft at least 12 months before study entry
  • ✓ Subjects with clinically diagnosed CLAD-BOS phenotype (all 3 required)
  • ✓ BOS defined as screening FEV1 between 85-51% of the baseline as defined by the 2 highest FEV1 measures at least 3 weeks apart.
  • ✓ Diagnosis within 12 months of screening visit.
  • ✓ FEV1 decline is persistent as defined by decline sustained for \> 30 days.
  • ✓ Currently receiving Standard Immunosuppression. This is defined as a combination of 3 medications including Prednisone, Mycophenolate or Azathioprine, and Tacrolimus or Cyclosporine. The dosing should be stable for 4 weeks prior to screening.
  • ✓ Absence of oral sirolimus or everolimus treatment for at least 4 weeks prior to screening based on the half-life and resolution of the tissue effects

You may not qualify if…

  • ✕ Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
  • ✕ Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • ✕ Patients with re-transplantation or currently listed for re-transplantation
  • ✕ Patients with confirmed other causes for loss of lung function, such as acute infection, acute rejection, restrictive allograft syndrome (CLAD - RAS phenotype, see Protocol Specific Definition), etc.
  • ✕ Patients with acute antibody-mediated rejection at Screening. In this context, clinically stable patients (as judged by the Investigator) with detectable donor-specific antibodies (DSA) levels at the Screening Visit are eligible for the study
  • ✕ Active acute bacterial, viral, or fungal infection that has not successfully resolved in at least 4 weeks prior to the Screening Visit. Patients with chronic infection or colonization who are clinically stable as per judgement of the investigator are eligible.
  • ✕ Mechanical ventilation within 12 weeks prior to the randomization
  • ✕ Patient has baseline resting oxygen saturation of \< 89% on room air or use of supplemental oxygen at rest at screening

Where it's recruiting

California

San Francisco

Source: ClinicalTrials.gov · NCT06018766 · last updated 2026-05-18

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Sy · TrialPath